Jazz Pharmaceuticals plc (JAZZ) Earnings Call Transcript & Summary

Citi Annual Global Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. We're pleased to have Jazz Pharmaceuticals with us. We have Philip Johnson, EVP and CFO. So welcome Phil. And then, we have Jack Spinks from Jazz as well. So thank you, guys for joining us. Phil, you want to kick it off with some kind of opening comments, and we can get right into some questions?

Happy to. Thank you very much for the invite. Pleasure to be here at the conference. In addition to having Jack with me from our IR team, I also want to give a shout out to John Bluth, who just recently joined us last week as our new Head of Investor Relations. So, we're pleased to have John onboard. A number of you may know him from different of his roles in the past, including most recently with BioCryst. So look forward to having a chance for you to get to know him further in his new role at Jazz. Maybe just to start out, a couple of disclaimers. Please do consult our most recent earnings call for more details on our business as well as our SEC filings, for a number of the risk factors that do affect our business. If we're referring to guidance during the discussion today, that would be referring to the guidance provided on our November 6, 3Q earnings call. And then we'll probably refer to some non-GAAP financials as well. And you can find in the earnings materials more complete reconciliations to the GAAP equivalents. Had a very strong quarter in the third quarter, record revenues for the company. Revenue is up about 7%, coming in at $1.13 billion. Really strong growth from our two largest brands, Epidiolex and the Xywav, strong growth underlying both of those from a demand perspective that gives us great momentum as we head into the back part of this year and then into 2026. We did on the back of that strong performance, we gave some updates to our guidance. We had narrowed the range for revenue given that we've gotten very few months left in the year, and everything was tracking to our expectations, took down the top and pulled up the bottom to give a tighter range there. We did go ahead and bring up our ANI and EPS guidance given the strong momentum and disciplined execution on expenses that we've been seeing through the year. And there had been some things also that generally had pulled up the overall level of results for the year. I want to highlight one in particular. That was a recognition in the third quarter of a $206 million deferred tax asset related to the Chimerix acquisition. One of the reasons why I bring this up is just to explain quickly what that is. Effectively, those are tax loss carryforwards and the tax attributes that Chimerix had that we'll be able to utilize to reduce our future tax liability by $206 million, providing another source of significant value from that acquisition, which is I'm sure we'll talk later. Modeyso, the main asset that we acquired with Chimerix is off to a phenomenal start. We're really excited with that initial performance. We also finished the quarter with about $2 billion in cash and investments for the first 9 months of the year, had about $1 billion of cash flow. That puts us in a great position to continue to do business development like we did with Chimerix. And then, as we think about things have happened since we had finished the third quarter in October. We got approval for the first-line maintenance indication for Zepzelca and then most recently and most notably, had the data readout for the first-line GEA trial for zanidatamab with very strong results. This was for those of you that have been following us or maybe not the final PFS readout in the first of three overall survival readouts. We're extremely pleased that for the doublet zanidatamab plus chemo. We show statistically significant, clinically meaningful progression-free survival and a very strong trend towards overall survival benefit as well, although not at this first interim reaching statistical significance. And then for the triplet in addition, adding on top trastuzumab had both clinically meaningful and static, progression-free survival as well as overall survival. We look forward to presenting the results in detail at an upcoming medical meeting in the first quarter of the year and feel like we did accomplish our objective in this study of showing that zanidatamab should become the HER2 treatment of choice in this first-line GEA setting supplanting Herceptin. Maybe I'll leave that for the opening remarks and see we'd like to go with the questions. But really, really pleased to be here talking about Jazz and the excitement we've got moving forward.

Sounds good. Thanks, Phil. Yes. So I guess let's go in reverse order maybe with respect to BD capital allocation, then we'll get obviously into the commercial portfolio. Talk a little bit about the Chimerix deal, kind of the rationale going into it, what were you guys looking for from a contribution perspective and talk about how the -- we have a strategic fit here.

Yes. So it really hit a number of things that we look for and we're looking for business development opportunities that we think we can be really successful with. There is a huge unmet need. This is one of few therapies in development for this particular mutation in this really rare form of glioma. And frankly, we had a little bit of controversy with it. There have been some physicians who have written the letter criticizing some of the development that may have scared some others away. That's not the kind of thing that Jazz will get scared away from. We dove in, in detail, got into diligence, looked at the data. We're very pleased with what we saw at a patient level in terms of durable responses of these patients we're seeing. The asset has really good patent protection, so a long-lived asset as well, another one of our criteria, a very focused call point, really built on a lot of things that we have in terms of capabilities, knowledge and experiences and felt we could be really successful with the launch of the product. There are some other things we saw as potential sources of value that frankly, we didn't put into the original model. And one of them I mentioned, the tax attributes that came with it as well, but we think this really lines up well for us to be able to contribute meaningfully to improving on patient care in an area where there's really been no new therapies available for about 60 years and bringing something that's meaningful. We'd love to be able to build upon this new presence for us in brain cancer and glioma. We'll look for opportunities to do that over time. Really been pleased with the colleagues at Chimerix that we've added to Jazz, a number of them who are staying in key positions for us moving forward and bringing great expertise in this area for us to continue to build on the success of Modeyso.

And then, I guess, same question on the SAN2355 licensing agreement. Talk about maybe the rationale there.

So Jazz had not been an epilepsy before the GW acquisition. We are a leader now because of that acquisition, the primary role that Epidiolex plays in the treatment of a number of these epilepsies, also a very combinable drug that's sort of a backbone other treatments can be added to. Not too long ago, we had greater clarity on exclusivity for Epidiolex out to the very late 2030s given the resolution with all the different ANDA filers. So certainly we want to make sure that we're building upon our presence there and have looked at a number of opportunities to do that and really liked the attributes in the Saniona molecule to potentially overcome some of the potential limitations for dosing, therefore, efficacy of other KB 7.2, 7.3 directed molecules and look forward to quickly advancing this through clinical development. We will, over time, look to build sort of more generally on the corporate development theme, the existing areas that we're present in. There are most opportunities probably in oncology and in epilepsy. There are a few opportunities given the state of the science in sleep. But there are some there as well. And then we have said in the past, we do continue to look at other areas within rare and orphan diseases, even if we're not there currently, where we could apply our capabilities and knowledge to be successful.

Yes. And talk a little bit about the kind of the BD climate today. There -- I mean, you guys are mostly focused on later-stage kind of assets. But are there new indications that are peripheral to the ones you're at or newer technologies that you feel like you could really add value, maybe that are in more mid-stage development versus later stage?

There are definitely -- from, I'd say, very early stage like we do with the Saniona deal, mid-stage to even later stage, even marketed opportunities that we see as really fitting well with Jazz. We are open to a range of transaction types. It doesn't have to be acquisition like we did with Chimerix, although we're certainly open to that. I feel we had a really successful well-structured deal, that shared risk and value appropriately between Zymeworks and Jazz for zanidatamab. We're certainly open to additional licensing deals like we did with the Saniona transaction. And it does not seem like there are as many sectors maybe where there's froth in valuations or outsized expectations. I think things are on a relatively even heel with sellers or licensors of assets at this point where it's more likely you can get to crossing on value.

Yes. Makes sense. Let's go to the commercial product performance. So Xywav, your overall sleep franchise has been growing quite nicely. Talk a little bit about the composition of new patients, maybe the mix between IH and narcolepsy and how you think that kind of evolves over time?

Yes. So, IH has been a real success story for Jazz. We're the only oxybate with Xywav that is approved for that indication. And it has been driving the majority of our new patient adds. In the most recent quarter, about 325 adds an IH and about 125 in narcolepsy and it is a place where we see the greatest opportunity for continued growth in patients for Xywav. In narcolepsy, we've been really pleased with our performance even in the face of authorized generic competition and additional branded competition. There had been a point in time where we're signaling to the Street that we could envision having met patient losses in narcolepsy given that competition. We actually not experienced that to date. And that speaks volumes to the benefit that Xywav offers is the only low sodium oxybate in a patient population in narcolepsy patients, IH is very similar, where those patients were at a 2x to 3x increased incidence of cardiovascular events. So certainly, having low sodium, less incidence of hypertension, we think, is a really important contributing factor to the overall health of these patients and a strong reason why Xywav has done so well, not only in idiopathic hypersomnia but also in narcolepsy. Going forward, as I said, we do see the bulk of the opportunity to add new patients in idiopathic hypersomnia. This is just based on the numbers that are available, a market that would appear to be about half the size of narcolepsy when you look at patients that are currently being treated, but we do hear reports from many physicians that they feel in their practice, they have as many IH patients as narcolepsy patients. And maybe as we're building this market, building awareness but there could be upside to those current number of patients being treated that could benefit from Xywav. I do want to mention, we talked about this on our quarterly call, we do hit this time point upcoming as we move into 2026, where there can be generic versions not of Xywav or low sodium oxybate, but of Xyrem, our high sodium oxybate. We do currently expect one or more generics to come into the market in 2026. And any impact on Xywav would be dependent upon the number of generics that come in, the timing in the year, what their pricing positions are. We feel we're well protected as well as we can be. Having established Xywav is really important with physicians and patients. based on being the only low sodium oxybate, but we do recognize payers may take actions depending on the opportunities that they have with the other generics that could create some headwinds for Xywav over the course of '26.

Just real quick on the IH indication. Do you feel like there is appreciation in the physician community about the subtleties of the indication and awareness? Or is there more sort of build to come from the commercial investment?

There's more, I think that we can do with some of the physicians to help them understand why you would use an oxybate for this particular patient population. I think, when they understand the kind of benefits that you're seeing in sleep and what that leads to in terms of the daytime benefits, they do understand then the rationale for it, but there are some who at face value might question, why would I use an oxybate with this particular patient population. But to date, those efforts have been going really well, and we'll continue to drive penetration in the IH market over time.

Awesome. Let's switch gears to Epidiolex. So talk a little bit about the drivers of growth here as you're about to hit blockbuster status for this. So it's a pretty impactful drug for you. What are the big drivers? And kind of what should the -- trend should be going into next year?

Yes. So, we're definitely on track to achieve blockbuster status. I believe it was maybe 11% growth year-to-date. We need 3% growth over last year effectively to hit blockbuster status. So, well on track to achieve that. We're seeing really good results from a number of initiatives that we have, some around ensuring that there is appropriate titration in the initial experiences that patients are having as they come on to Epidiolex. We have some nurse navigators that are assisting with that process, and we're seeing really good results with increased persistence in patients that are receiving that service. We've also increased some of the resources that we have that are providing more information on the benefits not only for seizure, but non-seizure benefits, making sure that some of the publications that we've been presenting at medical meetings are fully understood. The combinability of Epidiolex, again, as physicians are looking at things that they can use to treat their patients best, really using this as a backbone therapy and making sure that they understand not only again the seizure benefits, but the non-seizure benefits that come. Jack, and there's a couple of other things we may have talked about over time. I was wondering if you want to add any?

Yes. I think a focus of ours has been on patient identification. So, doing things like utilizing tools that healthcare providers can have to better diagnose patients, such as the REST-LGS tool has been really quite effective for us. We've also implemented commercial initiatives like the Nurse Navigator program, which really helps patients titrate through the initial course of therapy and really working to improve persistency across patients. So, there's a number of commercial initiatives that we've been working on.

LGS patients, in particular, are ones that often diagnosis can take over a decade. So that patient identification has been really key and that REST-LGS tool has been very helpful for physicians as they're trying to identify patients that could benefit from Epidiolex than potentially other anti-seizure medications as well.

Let's talk a little bit about the persistent rates. So, maybe how has that evolved over time? And what is sort of typical for the category?

So, we've not quantified the persistence. We have talked about pretty substantial increases in persistency in those patients that are using that Nurse Navigator program to titrate up and get to a therapeutically effective dose that gives them the kind of benefits that they're hoping for and expecting. But beyond that, we've not gotten into the specifics of the number of months of average persistence. Certainly, these are patients where there can be loss early on, those patients that once they're on and are perceiving benefit, they do tend to stay on for multiple years.

Yes. and then, the evolution to the adult -- more adult population. Talk a little bit about the growth opportunities there and maybe the timing of when you could see the impact of that?

So, we are already seeing some impact to our efforts to ensure that there's appropriate understanding of the benefit that can be particularly for LGS patients, for example, achieved in adult patients. We've had for the last couple of years, focus on some of the long-term care centers and other centers where these patients are most prevalent. And those efforts do continue. I'd say it's not a bolus. It's sort of like a bit like we're seeing with the IH population with Xywav, sort of a continual build over time as we get more and more awareness of the product for those patients, more and more physician experience treating those patients and seeing the benefits that Epidiolex can bring to those adult patients.

And Phil, you mentioned kind of the payer mix here as well. Talk a little bit about how that has evolved over the course of the past year or so on gross to net and on formulary positioning. Like -- this is a unique skill for you guys to try to get better access, but it's been a bit of a challenging environment right this year with some more policy uncertainty.

Yes. So I'd say, just from the pure payer perspective, apart from the policy side of things, compared to what I was used to prior to coming to Jazz, these are categories where the gross to net is nowhere near as high. It certainly exists, but it's not the same kind of both competitive intensity and then just mass market that leaves those very large gross to net reductions that you see with some of the primary care products. Our payer mix has not changed dramatically in the last few years. It depends on which product sort of our exposure to some of the government programs getting to some of the policy questions. To date, there is some potential exposure to some of the policy initiatives, most favored nations and things that have been discussed, but nothing has really been put concrete out there for us to really react to and to quantify. I would say Epidiolex is one of those products that does have a decent amount of some of the government pay. But I think compared to other maybe larger pharma, the exposure we have probably is proportionately not quite as large as they would have. On the policy side as well, obviously, unrelated to the pricing or gross to net, we've had discussions of tariffs for much of this year. As a company that has 90% of its revenue in the U.S. and much of its production outside, there are a lot of early interest and understanding steps that we could take to mitigate that exposure. We've significantly built and continue to inventories here in the U.S. to buffer any impact from tariffs to date and the most recent example being the U.K./U.S. agreement. I think, we're getting to things that seem much more reasonable and manageable, not some of the initial fears that had been put out with some of the very large tariff rates that were being represented by the administration. So at this point, we have a very manageable potential impact as we look forward into 2026 from tariffs as well. So not 0, but not something that's particularly concerning to us at this point in time.

So, you're comfortable with where Jazz is today on an MFN and a manufacturing. Have you guys talked about the level of investment with respect to onshoring that you could make?

So, there's been a lot of work done through bio primarily, I think making sure the administration understands that there are certain participants in the industry that are really well positioned to actually sink their own capital into the ground and build facilities. Some of the smaller and midsized players really aren't in that position and probably definitely open to and we are moving production to the U.S., but using third parties to do that. So, it is bringing employment to the U.S., in some cases, additional investment into the U.S., but not something being done directly by Jazz. It's possible for us in the future to potentially have our own U.S. site. I think, our first protocol would be to work with known, trusted, established contract manufacturing organizations that can do that work here in the U.S. We're already set up to have a CMO that can do all of our oxybate needs and have that supply up and running and are working on some other moves of that drug product manufacturing here to the U.S. as well for a number of products.

Okay. Let's switch gears to oncology. So Zepzelca, I wanted to ask you maybe about the small cell lung market, how that's evolved? How do you think this product -- there's some new entrants. This has been historically though, a tough indication, I think.

Definitely tough indication. I know, in one of the medical meetings this year, one of the people asking questions of the discussions after a couple of the presentations that they felt there had been more presented in that 1.5 hours or so block on advances in small cell lung cancer than they've seen for probably 30 years before. So, a lot of really exciting things for patients. We're very pleased to be participating in that. The first-line maintenance data with Zepzelca and atezolizumab, we think should become standard of care in that setting. As we've noted and presented, PFS benefit, OS benefit, very meaningful, significant advance for patients there. Now we're not the only one making advances in this area. Certainly, IMDELLTRA has had in the second-line setting, a similar PFS and OS benefit has been building its share. We'd expect that likely to continue. And then in the first-line setting, about 70% of patients are extensive stage. That's where we had studied Zepzelca, about 30% are limited stage. There's been some really stellar first-line data in extensive -- sorry, in limited stage with durvalumab that is giving great results for those patients, leading to fewer patients progressing into the second line. So, as we think about Zepzelca, very strong opportunity for us to benefit patients and build first-line maintenance share. But there in the second-line life, there will be fewer patients that are coming from limited stage, because of the durvalumab data and then greater share over time to IMDELLTRA with their second-line results. So, really excited for patients for what's happening in that segment of the market in small cell lung cancer and with the data that we've got for first-line maintenance.

So you have a combination, you have maybe more runway in the maintenance. What are maybe the other opportunities that you would see for growth, maybe line extensions?

For Zepzelca, I think just given the remaining patent life, it's unlikely that we would make substantial new investments in that product at this point in time. We do see, though, great growth in oncology for Jazz. But it'll be different molecules like Modeyso, Ziihera and others hopefully to come with our continued corp-dev efforts.

Yes, Modeyso, let's focus on that. So you've had a good initial launch. Talk about the initial physician feedback kind of positioning? Is it kind of what you thought?

Yes. We're real pleased. I'm going to let Jack take this one and get involved here.

Yes. Yes. Thanks, Geoff. We are really pleased with the initial uptake we've seen. It's been very strong since our approval on August 6. We did recognize $11 million in net sales in 3Q '25, and that's after being on the market for only a couple of weeks. That's about 200 patients, which is really exciting to see. I mean, there's huge unmet need here with existing treatments around for the last 60 years, this represents the first advance for patients with H3 K27M-mutant diffuse glioma in a very long time. So, it's been fantastic to see. The majority of those 200 patients were de novo patients, about 60%, with the other 40% coming over from EAP. And given that massive significant unmet need, we do have very strong relationships with patient advocacy and support organizations, which have helped drive that uptake. So,, I think, we're excited about the initial launch. We see this product as being around north of $500 million in peak sales. And then, there have been a number of initiatives ongoing to make sure we continue to drive that awareness and uptake.

I think it's a little too early at this point to change our peak sales expectations. But certainly, the initial uptake has exceeded our expectations. So really pleased with the results to date and the trajectory that we're on.

And there hasn't been really much in the way of limitations on diagnostics, right? I mean, it's a fairly straightforward path.

It is typically done on your academic centers. It's been part of the protocol for these patients for quite some time now. It's possible that not everyone was getting tested since there really was no product that was approved for the specific mutation. So, we're making sure that we're educating not only in the academic centers, but in community centers about testing for patients that may have this kind of mutation so that they can be identified as often as possible and then available to receive Modeyso.

And talk a little bit about the impact that you would see over time with sort of an OS benefit moving -- expanding the opportunity a little bit.

Yes. Jack, do you want to?

Yes. I think, we have an ongoing confirmatory trial, the ACTION trial in frontline, which would serve to confirm benefit in that second line post approval. We've talked about having OS results for that trial late '26, early '27. So, we're very excited about having that option for patients. Again, this is an extremely aggressive brain tumor. And while frequently tested for these patients are certainly in need of additional options. And we look forward to being able to bring additional options for patients in the front line with hopefully positive results from that ACTION trial.

And from maybe a guideline context, would that be another driver of growth? Or do you think it's mostly awareness and kind of patient testing as maybe the next, call it, 12 months or so?

So the awareness of the drug itself, I think, is extremely high, making sure that there is appropriate awareness of testing, is something we're focused on. This is one where there's strong enough awareness. Clearly, we promote to label. So, we will promote to first-line post getting the positive confirmatory study and then approval from the FDA. But we do know of physicians who have really no other choices. And there's probably some utilization that we'll have in this interim period in that first-line setting given physician choice, not motivated by Jazz actions. That could be part of what's driving some of the additional early uptake that is a bit beyond the expectations that we had originally. I think, it does speak to the strong unmet need and the confidence that physicians have in this product. Also, relatively benign safety profile, so very easy for them to administer. And again, we're seeing a relatively 20-some percent patient overall response rate, but within those, some very long and durable meaningful responses that are delivering significant benefit to these patients.

And the ACTION trial is going to take, I think, a little bit of time to mature. But are there any other studies that maybe you could continue to look to as they mature, maybe longer follow-up that could...

We are looking at other opportunities for Modeyso. And just real quick on the timeline for the ACTION study. We did make a determination that we wanted to have overall survival be the main endpoint for that study. We thought that was the most appropriate. So we did go ahead and increase the number of patients from 410 to 510. So, if you're comparing some of the prior statements that Chimerix had made on potential trial readout and comparing that to what we're talking about now, that's the driver for a bit of that shift out in time is for that additional patient accrual and then getting to the overall survival readout.

Got you. Okay. Let's switch gears to Rylaze. So walking down the oncology portfolio, talk a little bit about the growth drivers there when you look at the adolescent young adult setting.

Yes. So definitely, the adolescent young adult setting is the area where there's more opportunity for growth. For quite some time, Rylaze has been widely adopted in almost all of the pediatric protocols. So, within that AYA setting, those treating physicians are using a mix of asparaginase-based therapies or others. So, our efforts there have really been focused on ensuring that they understand the benefits of an asparaginase-based regimen and then the role for Rylaze, if they have any issues with their patients in that first-line asparaginase setting, hypersensitivity reaction in particular. So, it's been relatively stable in terms of the product given some of the overall dynamics we've seen to date, again, probably minimal opportunity for growth in that pediatric setting since we're highly penetrated there. We'll work to maintain that positioning and then increasingly look to drive penetration into the adolescent and young adult patient population.

And then, the switching component, maybe talk a bit about what -- kind of, what inning we're in with respect to that and how much you -- that could be a driver.

So the -- I think, the product here is really well positioned as the go-to after you've had hypersensitivity reaction in the first-line with one of the other asparaginase therapies. So that -- I don't -- at this point, I think that's sort of played out, and we're sort of into a steady state for that and the positioning is well known and respected and understood by physicians.

Yes. That makes sense. Phil, you mentioned we started off with a bit of a discussion on BD and oncology. Would you say if you had to rank them, would that be a therapeutic area that you probably would be most acutely focused on? And obviously, your -- the kind of history of Jazz is more in the rare disease space. How do you kind of look at those from an ROI perspective?

So, I'd say even before we get to ROI, just what's happening in terms of the science, there certainly is a lot going on in oncology, including in rare diseases. So it's a fertile area for us to continue to build just like we did with the acquisition of Chimerix and dordaviprone. Also quite a bit going on in epilepsies in terms of new mechanisms of action, improvement upon existing mechanisms of action. So, quite a bit of scientific substrate there. Sleep, the other main area that we've been in, frankly, there's less. There's sort of at this point in time, orexins and there's not a lot else. Now there are some things that are percolating in preclinical that could come to the fore over the coming years. But just for a scientific substrate, that's how I would view our current areas of participation. We have been looking -- I know we haven't done a deal yet. We have been looking in areas that are in rare and orphan diseases that aren't sleep epilepsy or oncology. And there is quite a bit of substrate there as well. So we're looking for opportunities for us, again, high unmet need, significant improvement upon standard of care, relatively limited call point, a lot of the things that characterize the product we've been successful with that we think could translate into a new therapeutic area for us as well. So there's certainly opportunities there. When you get to actually the return piece, there, I think it's probably more gated by at what point in time you're entering with your acquisition or your licensing. Clearly, as you get beyond proof-of-concept, things get a little more fully priced. So as you're accessing those, probably more of that value goes to the seller or the licensor. If you're pre-proof-of-concept, then obviously, you're taking more of that clinical risk and retaining more of that potential future value. In general, I'd say we're comfortable taking that earlier clinical risk, including preclinical in areas where we've got significant existing expertise like we did with the Saniona molecule in epilepsy.

And what are your thoughts on -- I think in the bigger pharma category, we've seen CVRs dominate a lot of activities in BD. And we've also seen assets coming from China that are more bio-buck, sort of, back-end loaded. What are your thoughts about the creative structures that we've seen and be what could Jazz use going forward?

Yes. Definitely open to structuring. CVRs, I think, have been used for quite some time, a little more in vogue at this point in time, probably more to bridge final discrepancies on value that typically not a large percentage of the overall deal value, but certainly something that's been employed in the past by Jazz and we'd be very open to that kind of structuring. And then definitely want to continue to build out the sources for innovation that we have access to. China, as you know is exploding, and that's one of the areas that I think we do need to continue to build our relationships into that market and innovators, particularly for those drugs that are going to be applicable to rare and orphan disease so that we're a port of call for them to come to with those opportunities as well.

And you mentioned upfront the strong cash position that you guys are in. So, do you have -- how do you balance that? Are investors more biased to investing internally in commercial? Or is it be aggressive on the external kind of BD M&A front?

So, I'd say if you ask 10 investors, you're going to get a variety of responses to that. In fact, Jack and I just recently have been on a CEO listening tour with Renée, our new CEO, both in person and then on video calls with investors. I would say the mass balance of those individuals expressed a strong interest in Jazz continuing to invest externally to bring in molecules that would be in their minds more innovative. And often Modeyso and Ziihera were cited as good examples of that kind of asset. Certainly, people across the board, I think, interested in understanding our plans to maximize the value of zanidatamab given this most recent first-line GEA readout. So I'd say don't drop the ball on the internal opportunities that you've already got, but definitely an expectation that we'll continue to build on the future growth prospects of the company through corporate development.

Awesome. Well, Phil, Jack, thank you very much, guys.

Yes. Thanks for having us.